MEManuel Etzkorn

Manuel Etzkorn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manuel Etzkorn has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Capturing G protein-coupled receptors into native lipid-bilayer nanodiscs using new diisobutylene/maleic acid (DIBMA) copolymers

    by Ci Chu, Carolyn Vargas, Maria Carolina Barbosa, Simon Sommerhage, Gerald N. Rechberger, David Pahovnik, Ema Žagar, Gunnar F. Schröder, Sandro Keller, Manuel Etzkorn


  • Open Access

    The coming of age of DNA‐based catalysts for therapeutic applications

    by Robert Hesse, Christoph G. W. Gertzen, Jessica Felice Schmuck, Justin Darvin Böcker, Piyush Pandey, Tobias Behn, Christopher Ruth, Detlev Riesner, Stephanie Kath‐Schorr, Philipp A. Lang, et al.

  • Open Access

    Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO with improved antiproliferative effect in RUNX-ETO positive cells

    by Mohanraj Gopalswamy, David Bickel, Niklas Dienstbier, Jia-Wey Tu, Melina Vogt, Stephan Schott-Verdugo, Sanil Bhatia, Manuel Etzkorn, Holger Gohlke

    The RUNX1/ETO fusion protein is a chimeric transcription factor in acute myeloid leukemia (AML) created by chromosomal translocation t(8;21)(q22;q22). t(8;21) abnormality is associated with 12% of de novo AML cases and up to 40% in the AML subtype M2. Previously, we identified the small-molecule inhibitor 7.44, which interferes with NHR2 domain tetramerization of RUNX1/ETO, restores gene expression down-regulated by RUNX1/ETO, inhibits proliferation, and reduces RUNX1/ETO-related tumor growth in a mouse model. However, despite favorable properties, 7.44 is negatively charged at physiological pH and was predicted to have low to medium membrane permeability. Here, we identified M23, M27, and M10 as non-charged analogs of 7.44 using ligand-based virtual screening, in vivo hit identification, biophysical and in vivo hit validation, and integrative modeling and ADMET predictions. All three compounds interact with the NHR2 domain, have K D, app values of 39–114 µM in Microscale Thermophoresis experiments, and IC 50 values of 33–77 µM as to cell viability in RUNX1/ETO-positive KASUMI cells, i.e., are ~ 5 to 10-fold more potent than 7.44. M23 is ~ 10-fold more potent than 7.44 in inhibiting cell proliferation of RUNX1/ETO-positive cells. Biological characterization of M23 in relevant RUNX1/ETO-positive -and negative cell lines indicates that M23 induces apoptosis and promotes differentiation in RUNX1/ETO-positive AML cells. M23 and M27 are negligibly protonated or in a ~ 1:1 ratio at physiological pH, while M10 has no (de-)protonatable group. The non-protonated species are predicted to be highly membrane-permeable, along with other favorable pharmacokinetic and toxicological properties. These compounds might serve as lead structures for compounds inhibiting RUNX1/ETO oncogenic function in t(8;21) AML.


  • Open Access

    Characterization of size-tuneable aescin-lipid nanoparticles as platform for stabilization of membrane proteins

    by Fatima Escobedo, Mohanraj Gospalswamy, Pia Hägerbäumer, Tim Julian Stank, Julian Victor, Georg Groth, Holger Gohlke, Carina Dargel, Thomas Hellweg, Manuel Etzkorn


  • Open Access

    The dynamic world of the 8–17 DNAzyme

    by Jessica Felice Schmuck, Jan Borggräfe, Manuel Etzkorn

    DNA catalysts, known as DNAzymes, have arguably been limited for decades by the lack of mechanistic information. The solution structure of the 8–17 DNAzyme reported by Wieruszekska, Pwlowicz et al. reassesses the current thinking regarding the relationship between structure, dynamic, and metal ion coordination.


  • Open Access

    Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO and exhibiting an improved, selective antiproliferative effect in RUNX-ETO positive cells

    by Mohanraj Gopalswamy, David Bickel, Niklas Dienstbier, Jia-Wey Tu, Stephan Schott-Verdugo, Sanil Bhatia, Manuel Etzkorn, Holger Gohlke

    The RUNX1/ETO fusion protein is a chimeric transcription factor in acute myeloid leukemia (AML) created by chromosomal translocation t(8;21)(q22;q22). t(8;21) abnormality is associated with 12% of de novo AML cases and up to 40% in the AML subtype M2. Previously, we identified the small-molecule inhibitor 7.44 , which specifically interferes with NHR2 domain tetramerization of RUNX1/ETO, restores gene expression down-regulated by RUNX1/ETO, inhibits proliferation, and reduces RUNX1/ETO-related tumor growth in a mouse model. However, despite generally favorable physicochemical, pharmacokinetic, and toxicological properties, 7.44 is negatively charged at physiological pH and was predicted to have low to medium membrane permeability. Here, we identified M23 , M27, and M10 as non-charged analogs of 7.44 using ligand-based virtual screening, in vivo hit identification, biophysical and in vivo hit validation, and integrative modeling and ADMET predictions. All three compounds interact with the NHR2 domain and show K D,app values of 39-114 µM in Microscale Thermophoresis experiments as well as IC 50 values of 33-77 μM as to cell viability in RUNX1/ETO-positive KASUMI cells, i.e., are ∼5 to 10-fold more potent than 7.44 . M23 is ∼10-fold more potent than 7.44 in inhibiting cell proliferation of RUNX1/ETO-positive cells. M23 and M27 are negligibly protonated or in a ∼1:1 ratio at physiological pH, while M10 has no (de-)protonatable group. The non-protonated species are predicted to be highly membrane-permeable, along with other favorable pharmacokinetic and toxicological properties. These compounds might serve as lead structures for the optimization of binding affinity, bioavailability, and anti-leukemic effects of compounds inhibiting RUNX1/ETO oncogenic function in t(8;21) AML.

  • Open Access

    Capturing G protein-coupled receptors into native lipid-bilayer nanodiscs using new diisobutylene/maleic acid (DIBMA) copolymers

    by Ci Chu, Carolyn Vargas, Maria Carolina Barbosa, Simon Sommerhage, Gunnar F. Schröder, Sandro Keller, Manuel Etzkorn

    Many membrane proteins, including G-protein-coupled receptors (GPCRs), are susceptible to denaturation when extracted from their native membrane by detergents. Therefore, alternative methods have been developed, including amphiphilic copolymers that enable the direct extraction of functional membrane proteins along with their surrounding lipids, leading to the formation of native lipid-bilayer nanodiscs. Among these amphiphilic copolymers, styrene/maleic acid (SMA) and diisobutylene/maleic acid (DIBMA) polymers have been extensively studied and successfully utilized to isolate various types of membrane proteins, including GPCRs. Despite their many benefits, SMA and DIBMA polymers also have significant drawbacks that limit their application. Most notably, both SMA and DIBMA carry high negative charge densities, which can interfere with protein–protein and protein–lipid interactions through unspecific Coulombic attraction or repulsion. Herein, we describe a series of new amphiphilic copolymers derived from DIBMA via partial amidation of the carboxylate pendant groups with various biocompatible amines. The nanodisc-forming properties of the new polymers were assessed using model membranes as well as in the context of extracting the melanocortin 4 receptor (MC4R), a prototypical class A GPCR. While each new DIBMA variant displays distinct features that may be favorable for selected applications, we identified a new PEGylated DIBMA variant called mPEG 4 -DIBMA as particularly promising for the studied purpose. On the one hand, mPEG 4 -DIBMA abolishes unspecific interactions with the tested peptide ligand, a prerequisite for reliably characterizing GPCR–ligand interactions. On the other hand, mPEG 4 -DIBMA outperforms other polymers such as SMA and DIBMA by achieving higher extraction efficiencies of MC4R from Sf9 insect cell membranes. Thus, this new nanodisc-forming polymer combines two key advantages that are crucial for investigating GPCRs in a well-defined but still native lipid-bilayer environment, thus paving the way for manifold future applications.


  • RNA-Processing DNAzymes

    by Ingrid Span, Manuel Etzkorn

  • Open Access

    The architecture of the 10‐23 DNAzyme and its implications for DNA‐mediated catalysis

    by Jan Borggräfe, Christoph G. W. Gertzen, Aldino Viegas, Holger Gohlke, Manuel Etzkorn

    Understanding the molecular features of catalytically active DNA sequences, so‐called DNAzymes, is essential not only for our understanding of the fundamental properties of catalytic nucleic acids in general, but may well be the key to unravelling their full potential via tailored modifications. Our recent findings contributed to the endeavour to assemble a mechanistic picture of DNA‐mediated catalysis by providing high‐resolution structural insights into the 10‐23 DNAzyme (Dz) and exposing a complex interplay between the Dz's unique molecular architecture, conformational plasticity, and dynamic modulation by metal ions as central elements of the DNA catalyst. Here, we discuss key features of our findings and compare them to other studies on similar systems.


  • Open Access

    Electroneutral Polymer Nanodiscs Enable Interference‐Free Probing of Membrane Proteins in a Lipid‐Bilayer Environment

    by David Glueck, Anne Grethen, Manabendra Das, Ogochukwu Patricia Mmeka, Eugenio Pérez Patallo, Annette Meister, Ritu Rajender, Stefan Kins, Markus Räschle, Julian Victor, et al.

    Membrane proteins can be examined in near‐native lipid‐bilayer environments with the advent of polymer‐encapsulated nanodiscs. These nanodiscs self‐assemble directly from cellular membranes, allowing in vitro probing of membrane proteins with techniques that have previously been restricted to soluble or detergent‐solubilized proteins. Often, however, the high charge densities of existing polymers obstruct bioanalytical and preparative techniques. Thus, the authors aim to fabricate electroneutral—yet water‐soluble—polymer nanodiscs. By attaching a sulfobetaine group to the commercial polymers DIBMA and SMA(2:1), these polyanionic polymers are converted to the electroneutral maleimide derivatives, Sulfo‐DIBMA and Sulfo‐SMA(2:1). Sulfo‐DIBMA and Sulfo‐SMA(2:1) readily extract proteins and phospholipids from artificial and cellular membranes to form nanodiscs. Crucially, the electroneutral nanodiscs avert unspecific interactions, thereby enabling new insights into protein–lipid interactions through lab‐on‐a‐chip detection and in vitro translation of membrane proteins. Finally, the authors create a library comprising thousands of human membrane proteins and use proteome profiling by mass spectrometry to show that protein complexes are preserved in electroneutral nanodiscs.